So it would appear they do have just enough money to make it to the end of the year. But only just.
They had 8.26 million as of Dec 31 2020. Then got 5 million, so 13.26 million.
They had a burn last year of about 4 million per quarter. Giving them 1.26 million expected at end Dec 31 2021.
They also expect R&D costs to go up in 2021 vs 2020, so probs just just enough money to get them to December.
Does anybody have ok communications with CANF IR, ask them how things are going with the Piclidenoson recruitment? I believe Topline data was slated for end of year 2021. They mentioned spending considerable funds on "accelerating rate of absorption of patients for the Phase III clinical trial of Piclidenoson".
If we don't hear about the rate of enrollment then this likely gets delayed as they have been epically slow on recruitment.
If however they are recruiting well then that could turn the tides on deciding to invest.
News 
Market Data 
Discover 
